Genomic Analysis of Tumors from Patients with Glioblastoma with Long-Term Response to Afatinib

References

• Bleeker FE, Molenaar RJ, Leenstra S. Recent advances in the molecular understanding of glioblastoma. J Neurooncol. 2012;108(1):11–27. doi:10.1007/s11060-011-0793-0
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol. 2017;19(Suppl5):v1–v88. doi:10.1093/neuonc/nox158
   PubMed Web of Science ®Google Scholar
• Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma: are we there yet? Neuro Oncol. 2013;15(1):4–27. doi:10.1093/neuonc/nos273
   PubMed Web of Science ®Google Scholar
• Parker NR, Khong P, Parkinson JF, Howell VM, Wheeler HR. Molecular heterogeneity in glioblastoma: potential clinical implications. Front Oncol. 2015;5:55. doi:10.3389/fonc.2015.00055
   PubMed Web of Science ®Google Scholar
• McNamara MG, Sahebjam S, Mason WP. Emerging biomarkers in glioblastoma. Cancers. 2013;5(3):1103–1119. doi:10.3390/cancers5031103
   PubMedGoogle Scholar
• Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462–477. doi:10.1016/j.cell.2013.09.034
   PubMed Web of Science ®Google Scholar
• Eskilsson E, Rosland GV, Solecki G, et al. EGFR heterogeneity and implications for therapeutic intervention in glioblastoma. Neuro Oncol. 2018;20(6):743–752. doi:10.1093/neuonc/nox191
   PubMed Web of Science ®Google Scholar
• Xu H, Zong H, Ma C, et al. Epidermal growth factor receptor in glioblastoma. Oncol Lett. 2017;14(1):512–516. doi:10.3892/ol.2017.6221
   PubMed Web of Science ®Google Scholar
• Heimberger AB, Hlatky R, Suki D, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res. 2005;11(4):1462–1466. doi:10.1158/1078-0432.Ccr-04-1737
   PubMed Web of Science ®Google Scholar
• Pelloski CE, Ballman KV, Furth AF, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol. 2007;25(16):2288–2294. doi:10.1200/jco.2006.08.0705
   PubMed Web of Science ®Google Scholar
• Reardon DA, Wen PY, Mellinghoff IK. Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. Neuro Oncol. 2014;16(Suppl8):viii7–13. doi:10.1093/neuonc/nou232
   PubMed Web of Science ®Google Scholar
• Westphal M, Maire CL, Lamszus K. EGFR as a target for glioblastoma treatment: an unfulfilled promise. CNS Drugs. 2017;31(9):723–735. doi:10.1007/s40263-017-0456-6
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens AC, Bady P, et al. Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib–a Phase II trial. Mol Cancer Ther. 2011;10(6):1102–1112. doi:10.1158/1535-7163.Mct-11-0048
   PubMed Web of Science ®Google Scholar
• Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of Afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012;343(2):342–350. doi:10.1124/jpet.112.197756
   PubMed Web of Science ®Google Scholar
• Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008;27(34):4702–4711. doi:10.1038/onc.2008.109
   PubMed Web of Science ®Google Scholar
• Hochmair M. Medical treatment options for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer suffering from brain metastases and/or leptomeningeal disease. Target Oncol. 2018;13(3):269–285. doi:10.1007/s11523-018-0566-1
   PubMed Web of Science ®Google Scholar
• Reardon DA, Nabors LB, Mason WP, et al. Phase I/randomized phase II study of Afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro Oncol. 2015;17(3):430–439. doi:10.1093/neuonc/nou160
   PubMed Web of Science ®Google Scholar
• Saran F, Welsh L, James A, et al. Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial. J Neurooncol. 2021;155(3):307–317. doi:10.1007/s11060-021-03877-6
   PubMed Web of Science ®Google Scholar
• Alshami J, Guiot MC, Owen S, et al. Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report. Oncotarget. 2015;6(32):34030–34037. doi:10.18632/oncotarget.5297
   PubMedGoogle Scholar
• Goike HM, Asplund AC, Pettersson EH, Liu L, Sanoudou D, Collins VP. Acquired rearrangement of an amplified epidermal growth factor receptor (EGFR) gene in a human glioblastoma xenograft. J Neuropathol Exp Neurol. 1999;58(7):697–701. doi:10.1097/00005072-199907000-00003
   PubMed Web of Science ®Google Scholar
• Goike HM, Asplund AC, Pettersson EH, Liu L, Ichimura K, Collins VP. Cryopreservation of viable human glioblastoma xenografts. Neuropathol Appl Neurobiol. 2000;26(2):172–176. doi:10.1046/j.1365-2990.2000.026002172.x
   PubMed Web of Science ®Google Scholar
• Cho J, Pastorino S, Zeng Q, et al. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. Cancer Res. 2011;71(24):7587–7596. doi:10.1158/0008-5472.CAN-11-0821
   PubMed Web of Science ®Google Scholar
• Felsberg J, Hentschel B, Kaulich K, et al. Epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified glioblastomas: prognostic role and comparison between primary and recurrent tumors. Clin Cancer Res. 2017;23(22):6846–6855. doi:10.1158/1078-0432.Ccr-17-0890
   PubMed Web of Science ®Google Scholar
• Vengoji R, Macha MA, Nimmakayala RK, et al. Afatinib and temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. J Exp Clin Cancer Res. 2019;38(1):266. doi:10.1186/s13046-019-1264-2
   PubMed Web of Science ®Google Scholar
• Lee JC, Vivanco I, Beroukhim R, et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006;3(12):e485. doi:10.1371/journal.pmed.0030485
   PubMed Web of Science ®Google Scholar
• Agazie YM, Hayman MJ. Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. Mol Cell Biol. 2003;23(21):7875–7886. doi:10.1128/mcb.23.21.7875-7886.2003
   PubMed Web of Science ®Google Scholar
• Schulze WX, Deng L, Mann M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol. 2005;2005.0008(1). doi:10.1038/msb4100012
   Web of Science ®Google Scholar
• Yang F, Xu M, Wang S, et al. Gain-of-function E76K-mutant SHP2 promotes cell proliferation, metastasis, and tumor growth in glioblastoma through activation of the ERK/CREB pathway. Onco Targets Ther. 2019;12:9435–9447. doi:10.2147/ott.S222881
   PubMed Web of Science ®Google Scholar
• Furcht CM, Buonato JM, Skuli N, et al. Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells. J Cell Sci. 2014;127(Pt 16):3555–3567. doi:10.1242/jcs.150862
   PubMed Web of Science ®Google Scholar
• Weller M, Hentschel B, Kaulich K, et al. EGFR gene amplification and variant III (EGFRvIII) mutation in primary and recurrent glioblastoma. J Clin Oncol. 2016;34(Suppl15):2042. doi:10.1200/JCO.2016.34.15_suppl.2042
   Web of Science ®Google Scholar
• Yang JC, Sequist LV, Zhou C, et al. Effect of dose adjustment on the safety and efficacy of Afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. Ann Oncol. 2016;27(11):2103–2110. doi:10.1093/annonc/mdw322
   PubMed Web of Science ®Google Scholar
• Schuler M, Tan EH, O’Byrne K, et al. First-line Afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of Afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. J Cancer. Res Clin Oncol. 2019;145(6):1569–1579. doi:10.1007/s00432-019-02862-x
   PubMed Web of Science ®Google Scholar
• Halmos B, Tan EH, Soo RA, et al. Impact of Afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: results from a global real-world study (RealGiDo). Lung Cancer. 2019;127:103–111. doi:10.1016/j.lungcan.2018.10.028
   PubMed Web of Science ®Google Scholar